MedTrace Logo

Study of the Imaging Agent 18F-Var3 in Patients With Breast Cancer

NCT04054986 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2025-05-16

No results posted yet for this study

Summary

The purpose of this study is to measure the safety of the investigational imaging agent, 18F-Var3 and to determine if it is helpful in providing information about how tumor tissues behave.

Conditions

Interventions

DIAGNOSTIC_TEST

F-Var3 PET/CT

Participants will undergo up to 5 serial F-Var3 PET/CT scans within 25 minutes of the injection of 18F-Var3, 30, 60, 120 and 240 minutes after injection of the 18FVar3.

OTHER

Blood draw

Collection of blood for research tests before the injection, 30, 60, 120 and 240 min after the injection.

Sponsors & Collaborators

Principal Investigators

  • Christopher Riedle, MD, PhD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-09
Primary Completion
2020-09-18
Completion
2020-09-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04054986 on ClinicalTrials.gov